

William T. Abraham, M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.
Professor of Internal Medicine, Physiology and Cell Biology
Chair of Excellence in Cardiovascular Medicine
Associate Dean for Clinical Research
Chief, Division of Cardiovascular Medicine
Medical Director, Clinical Trials Management Office
Deputy Director, Dorothy M. Davis Heart and Lung Research Institute
The Ohio State University, Columbus, Ohio

Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado Health Sciences Center. He previously held leadership positions at the University of Colorado, the University of Cincinnati, and the University of Kentucky. At the Ohio State University, Dr. Abraham holds several leadership positions including an Associate Dean position, managing the College of Medicine's non-cancer clinical and translational research portfolio. As Division Director, Dr. Abraham has developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S.

Clinically, Dr. Abraham is board certified in Internal Medicine, Cardiovascular Diseases, and Advanced Heart Failure and Transplant Cardiology. He spends the majority of his clinical time managing heart failure patients in the inpatient and outpatient settings. Dr. Abraham has been recognized as one of the "Best Doctors in America" for fourteen consecutive years and has been ranked among the top 10% of physicians nationally in patient satisfaction.

Dr. Abraham's research program focuses on elucidating basic mechanisms in heart failure and on clinical drug and device trials in heart failure. Dr. Abraham has received grants from the National Institutes of Health (NIH) including current NIH funding, the American College of Cardiology, and the Aetna Quality Care Foundation. He has made major contributions to advancing clinical science and patient care in heart failure in at least three areas: device development in heart failure; neurohormonal therapies in heart failure including beta-blockers, natriuretic peptides, and vasopressin receptor antagonists; and acute heart failure and renal dysfunction complicating heart failure. His work has contributed to the approval and adoption of several new therapies for heart failure, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, and implantable hemodynamic monitoring devices.

Dr. Abraham has authored more than 900 original papers, abstracts, book chapters, and review articles. His work has been published in high impact journals, including *The New England Journal of Medicine*, *The Lancet*, *the Journal of the American Medical Association*, *Circulation*, *the European Heart Journal*, and *the Journal of the American College of Cardiology*. Dr. Abraham has co-authored national heart failure practice guidelines and co-edited a leading textbook on heart failure entitled [Heart Failure: A Practical Approach to Treatment](#) and serves as series editor for the [Color Atlas and Synopsis of Cardiovascular Medicine](#). Dr. Abraham serves on the editorial boards of several major journals. In 2014, 2015, and 2016, he was named to the Thomson Reuters Highly Cited Researchers¹ list and as one of The World's Most Influential Scientific Minds.

¹Highly Cited Researchers represents some of world's leading scientific minds. Only 3,000 researchers worldwide earned the distinction by writing the greatest numbers of reports officially designated by Essential Science Indicators as Highly Cited Papers—ranking among the top 1% most cited for their subject field and year of publication, earning them the mark of exceptional impact.